Directions: Take one to two capsules daily depending on severity of symptoms or as professionally directed. Not suitable for children 2 years and under Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle.
Contains no added sugar, salt, starch, gluten, synthetic flavours, artificial colours or preservatives.
Saccharomyces boulardii is a natural and safe probiotic yeast with extensive scientific research and documentation on its benefits in supporting bowel health, comfort and function.
S. boulardii has been internationally acclaimed as the number one probiotic for diarrhoea - to reduce discomfort and urgency and restore regular bowel movements.
Extra strength S. boulardii is a natural probiotic food supplement and NOT an antidiarrhoeal or anti-motility medicine – it will not artificially reduce the muscular contractions of the intestine to stop diarrhoea. It is a completely natural probiotic food supplement offering support for bowel health and comfort.
How does it work?
Saccharomyces boulardii – a unique probiotic yeast which is sold widely in the US, Scandinavia, Germany & France. S. boulardii has undergone extensive clinical research proving its ability to flush out pathogenic bacteria such as E. coli and salmonella and it's therapeutic benefits against diarrhoea.
DTECTA guarantees 5 billion live micro-organisms per S.boulardii vegetarian capsule until the best before date.
Diarrhoea can be defined as an increase in the frequency and amount of loose stools. It can be caused by a virus or bacteria – usually due to the ingestion of contaminated drinking water, undercooked meat and eggs or poor standards of hygiene.
If these situations occur, the body’s reaction is twofold - Introduce large amounts of water into the large intestines, and make the intestines more active by contracting frequently and irregularly, in order to flush out irritable micro-organisms, which results in diarrhoea.
Clinical Information / Research to support the use of Saccharomyces boulardii for diarrhoea
McFarland, L.V. & Bernasconi, P. (1993) Saccharomyces boulardii: A Review of an Innovative Biotherapeutic Agent. Microbial Ecology in Health and Disease; Vol. 6 pp. 157-171.
Hochter, W. et al (1990) Saccharomyces boulardii in acute adult diarrhea. Efficacy and tolerance of treatment. Munchener Medizinische Wochenschrift; Vol. 132 (12) pp. 188-192.
Cetina-Sauri, G. & Basto, S. (1994) Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Annales de Pediatrie; Vol. 41 (6) pp. 397-400.
Kurugol, Z. & Koturoglu, G. (2005) Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Paediatrica; Vol. 94 pp. 44-47.
Guslandi, M., Giollo, P. & Testoni, P.A. (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology & Hepatology. Vol. 15 pp. 697 – 698.
Maupas, J.L., Champemont, P. & Delforge, M. (1983) Treatment of Irritable Bowel Syndrome (IBS) Double Blind Trial of Saccharomyces Boulardii. Medecine Chirurgie Digestives. Vol. 12 (1) pp. 77 – 79.
McFarland, L.V. et al (1994) A randomised placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. The Journal of the American Medical Association. Vol. 271. pp. 1913 - 1918
Surawicz, C.M. et al (2000) The Search for a Better Treatment for Recurrent Clostridium difficile Disease: Use of High-Dose Vancomycin Combined with Saccharomyces boulardii. Clinical Infectious Diseases. Vol. 31 pp. 1012 – 1017
Buts, J., Corthier, G. & Delmee, M. (1993) Saccharomyces boulardii for Clostridium difficile-Associated Enteropathies in Infants. Journal of Pediatric Gastroenterology and Nutrition. Vol. 16 pp. 419 – 425
Surawicz, C.M. et al (1989) Treatment of Recurrent Clostridium difficile Colitis with Vancomycin and Saccharomyces boulardii. The American Journal of Gastroenterology. Vol. 85 (10)
Surawicz, C.M. (2003) Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Practice & Research Clinical Gastroenterology. Vol. 17 (5) pp. 775 – 783
